Science
Mechanism of Action
Piperlongumine acts at a cellular level to bolster skin barrier integrity by upregulating the mRNA expression of key genes like filaggrin (FLG) and involucrin (IVL). It also stimulates the synthesis of essential ceramides via enzymes such as CERS2. Beyond barrier support, it exhibits anti-proliferative and anti-inflammatory actions by inducing ROS-mediated late apoptosis in keratinocytes and inhibiting STAT3 and Akt signaling pathways. Notably, its mechanism can also involve increasing the secretion of specific pro-inflammatory proteins, necessitating a precise formulation strategy.
Research
Clinical Evidence
Medium confidenceN/A
Key findings
- 01 In HaCaT cells and human primary keratinocytes, 48 hours of treatment at 2% O2 increased mRNA expression of genes critical for skin barrier function (FLG, IVL) and ceramide synthesis (CERS2).
- 02 Inhibited keratinocyte hyperproliferation and differentiation, induced ROS-mediated late apoptosis, and suppressed STAT3 and Akt signaling pathways, suggesting anti-proliferative and anti-inflammatory potential relevant for conditions like psoriasis.
Transparency
Dusting Analysis
No data available to assess dusting potential or associated red flag percentages for this ingredient.
The Formula
Formulation
Stability
Maximum stability is observed around pH 4, with significant degradation occurring at pH values outside the 3-7 range. The ingredient is highly susceptible to photo-degradation upon UV light exposure, particularly in aqueous solutions, necessitating opaque packaging. Aqueous formulations should be prepared fresh and not stored for extended periods (e.g., beyond one day).
Conflicts
- Significant instability outside the pH range of 3-7
- Marked photo-degradation with UV light exposure
- Potential to enhance pro-inflammatory proteins (GRO-αβγ) in inflammatory conditions
Safety
Safety Profile
No specific safety assessments by CIR or SCCS have been identified. While cosmetic ingredients generally do not require FDA approval prior to marketing (excluding color additives), piperlongumine has an Orphan Drug Designation from the FDA for malignant glioma, which is a drug status and not indicative of cosmetic safety. When extracted, piperlongumine may cause skin, eye, or respiratory tract irritation. Due to its capacity to enhance pro-inflammatory proteins (GRO-αβγ), careful consideration of concentration and application in inflammatory skin conditions is crucial.
Your Skin
Skin Compatibility
Our Assessment
Verdict
While exhibiting promising in vitro benefits for skin barrier and ceramide synthesis, piperlongumine's significant formulation challenges (pH, photodegradation), potential for irritation when extracted, and capacity to increase pro-inflammatory proteins warrant extensive research and extremely precise formulation before widespread cosmetic application.
Related
Similar Ingredients
Finding similar ingredients…
References
Sources